A bold plan to restore affordability, innovation, and integrity to the American healthcare system.
Joined July 2025
- Tweets440
- Following32
- Followers110
- Likes1
Pinned Tweet
Our scorecard illustrates how countries like the UK, France, Germany, & Japan pay too little for innovative medicines, leaving American patients to carry a disproportionate share of drug development costs. @kerpen @SteveForbesCEO @StephenMoore
Learn more: mostfavoredpatient.org/resou…
Most Favored Patient retweeted
Foreign freeloading is creating larger barriers for seniors to access innovative medicines & treatments. @MFPatient's new scorecard with @Comm4Prosperity tracks how some countries are answering @POTUS's call to end the free-riding. @kerpen
Check it out: mostfavoredpatient.org/inter…
Most Favored Patient retweeted
NEW: @MFPatient scorecard reveals which countries have answered @POTUS' call to end foreign freeloading on American innovation.
Through trade negotiations, the US has made a deal with the UK to put patients first. Germany, Japan, and France have not yet done so.
See the full scorecard: mostfavoredpatient.org/inter…
JUST IN: Ahead of midterms, MFP released a new scorecard that tracks and ranks foreign countries on drug pricing, patient access, and whether each has answered @POTUS's call to end foreign freeloading. @Comm4Prosperity
Read the press release here:
mostfavoredpatient.org/resou…
COINS was built to keep US money out of China’s military tech. Stretching it to cover #Rx investment is a terrible idea. Cutting off these deals won’t stop breakthroughs. It just hands them to Chinese companies. Read more in MFP's recent statement on the extension. @kerpen @USTreasury mostfavoredpatient.org/resou…
Really, @AARPadvocates? Rising premiums, deductibles & copays are older Americans' top health care concern, yet 0 questions in @AARP poll. Wake up! AARP is paid BILLION$ via insurer-PBM UnitedHealth (under DOJ investigation). How’s this ok? @kerpen @costplusdrugs @Statnews @WSJopinion
IRA drug price "negotiations" are really price controls that distort market signals and inhibit development of new medicines. "Bringing a new drug to market can cost upwards of $2 billion. If the likelihood of recouping that investment shrinks, so too does the motivation to innovate." @NRO
nationalreview.com/2026/10/b…
“As the world's largest market for pharmaceuticals, America finds itself in the unique position of accruing the lion's share of the benefits from new medicines. We often recoup these additional costs in the form of longer and healthier lives,” says @USCSchaeffer's Dana Goldman. Importing foreign drug price controls will threaten these lifesaving benefits.
realclearmarkets.com/article…
America is the global leader of medical innovation, but not by accident. It is the result of deliberate policy choices that reward innovation, and it has delivered breakthrough treatments for patients.
China is rapidly gaining ground on the U.S. We must say no to price controls that would further cede leadership to them. @RepBenCline
washingtontimes.com/news/202…
Patients are already paying too much for health care. Now big insurers like @UHC are raising out-of-pocket costs, cutting benefits and narrowing access to doctors and hospitals.
Enough. Congress needs to rein in insurers and put patients first. @bobjherman @statnews statnews.com/2026/10/01/medi…
Importing Europe’s price controls with Most Favored Nation pricing will not fix U.S. healthcare costs. @SenateGOP & @HouseGOP "should instead focus on a reform that is already reducing patients' prices: direct-to-consumer (DTC) pharmaceutical sales." More:
realclearhealth.com/articles…
Tying U.S. drug prices to foreign price controls through Most Favored Nation could "threaten jobs, undermine manufacturing investment and weaken U.S. drugmakers' ability to compete with China." Patients need free-market solutions. @kerpen @FoxNewsOpinion
foxnews.com/opinion/trump-lo…
Most Favored Patient retweeted
More @AARP political cover for Democrat/AARP/big insurer-PBM alliance. Anyone find it odd premiums, deductibles & copays = biggest HC concern for 55+, but AARP says little while being paid BILLIONS via UnitedHealth? @dcexaminer @kerpen @WhiteHouse @DrOzCMS washingtonexaminer.com/op-ed…
Most Favored Patient retweeted
.@AARP claims expanding Medicare price controls will save billions, but those so-called savings come at the expense of investment in R&D.
Less R&D means fewer groundbreaking treatments reach patients, especially the seniors who need them most.
Price controls cannot achieve what a free market does: more competition, continued medical innovation, and more affordable options. washingtonexaminer.com/op-ed…
Expanding IRA drug price controls, which @AARP is lobbying Dems for, could have devastating effects on critical R&D. MFP's Tomas Philipson found that increasing price controls could prevent the development of 219 new drugs over a decade. @PatriciaGBarnes
washingtonexaminer.com/op-ed…
Polling says "72% of voters agree it’s time to make other countries pay their fair share for prescription drugs. Voters want Congress to act." Start with the USTRx Act—it confronts foreign freeloading head-on w/out importing foreign price controls. @kerpen
washingtonexaminer.com/op-ed…
Health care will be the issue of the midterms, so what do voters think? Republicans' small-government, patient-first approach is a winner, and the "government should keep focusing on giving people more control over their healthcare spending.” @newtgingrich
cahc.net/resources/new-voter…
.@jwhite_health nails it: "The lesson from the Inflation Reduction Act and other countries around the world is simple: Government drug price controls do not improve patient access. In many cases, price controls create incentives to ration care..." @C4AHC
thehill.com/opinion/healthca…
Health care is a winning issue for Republicans. Like @newtgingrich said: "the healthcare system should work for the person, not the bureaucracy." Think free-market system focused on lower costs, patient choice, and transparency. @Gingrich360
gingrich360.net/p/how-to-win…
